BMSCs protect against liver injury via suppressing hepatocyte apoptosis and activating TGF-ß1/Bax singling pathway.

Many factors cause liver injury, including chronic consumption of alcohol, irregular use of drugs, excessive levels of arsenic in water. This study aims to investigate role of bone marrow-derived mesenchymal stem cells (BMSCs) in liver injury recovery and to explore mechanism. BMSCs and primary hepatocytes were isolated, cultured and identified. Hepatocyte model and hepatic fibrosis (HF) model were established using carbon tetrachloride (CCL-4). The role of BMSCs were investigated in both in vitro and in vivo levels. Cell proliferation was examined using MTT assay. Transforming growth factor-ß1 (TGF-ß1), Bcl-2 and Bax expression were detected using western blot and real-time PCR, respectively. Results indicated that BMSCs and primary hepatocytes were successfully isolated and identified, and hepatocyte model was successfully established. BMSCs and HGF treatment enhance viability of normal hepatocytes and hepatocyte injury model. Cell viability in BMSCs treatment and Bax-1 inhibitor treatment group was higher significantly compared to normal hepatocyte control and injury hepatocyte model, respectively (P<0.05). Bax-1 expression was significantly lower and Bcl-2 was significantly higher in Bax-1 inhibitor treatment and BMSCs treatment group compared to normal hepatocyte control (normal rats) and injury hepatocyte model (HF model), respectively (P<0.05). BMSCs significantly decreased ALT and AST levels compared to Saline group (P<0.05). In conclusion, function of BMSCs in liver injury was triggered by inhibiting hepatocyte apoptosis and leading cell proliferation through TGF-ß1/Bax singling pathway. Our study proved protective role of BMSCs against liver injury via TGF-ß1/Bax pathway, which would enrich application of BMSC in clinical.

Primary leiomyosarcoma of the inferior vena cava: a case report.

Primary leiomyosarcoma of the inferior vena cava (IVC) is a rare malignant tumor originating from the vein smooth muscle. We present one case of primary leiomyosarcoma of the IVC. The patient benefited of surgical exploration at seventh day after admission. Tumor located in the junction of the anterior wall of the IVC and the left and right renal vein. We carried out the tumor resection, vena cava artificial vascular patch prosthetics. The patient did not take anticoagulant drugs after surgery and was discharged at 12 days after surgery. Currently, the patient had survived for nearly six months, repeated abdominal computed tomography examinations showed no clear recurrence.

[Treatment of focal bone defect in postoperative nonunion with autologous red bone marrow injection].

OBJECTIVE: To observe the clinical effect of autologous red bone marrow injection in treating focal bone defect in postoperative nonunion. METHODS: Thirteen patients with focal bone defect in postoperative nonunion (7 cases in tibia, 2 cases in femur, 4 cases in humerus), including 8 males and 5 females with the mean age of 32.5-years-old (ranging from 15 to 60 years). The bone defects were treated with autologous red bone marrow injection (1 time per 2 weeks, 5 times in total) and the X-rays of AP and LP were observed. RESULTS: Thirteen patients were followed up from 6 to 12 months with an average of 7.5 months. According to results of X-ray pictures, 13 cases obtained bone defect recovered completely, and the average time of union was 4 months. CONCLUSION: Autologous red bone marrow injection has ascendancy such as less wound and clear clinical effect, which can accelerate bone healing and promotes functional recovery of limb. It is a good method to treat focal bone defect in postoperative nonunion.